Publication
Miao et al. Science 2019
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CBIOPORTAL-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- cancerClear Cell Renal Cell Carcinomacbioportal_study1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29301960
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PBRM1 Mutation1 | ||||||||
| Anti-PD-L1 Monoclonal Antibody + CTLA-4 InhibitorSubstitutes | Clear Cell Renal Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7247Clinical benefit to immune checkpoint blockade was associated with loss-of-function mutations in the PBRM1 gene (P = 0.012), which encodes a subunit of the PBAF switch-sucrose nonfermentable (SWI/SNF)… (full text at CIViC) PMID 29301960 · Miao et al., 2018 · Open in CIViC | civic |
| PBRM1 Loss-of-function3 | ||||||||
| Atezolizumab + DurvalumabSubstitutes | Renal Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7537Among 35 patients with clear cell RCC, loss-of-function mutation of PBRM1 were correlated with response to anti-PD-1 monotherapy (P = 0.012). It was confirmed in an independent validation cohort of 63… (full text at CIViC) PMID 29301960 · Miao et al., 2018 · Open in CIViC | civic |
| Ipilimumab | Renal Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7301Among 35 patients with clear cell RCC, loss-of-function mutation of PBRM1 were correlated with response to anti-PD-1 monotherapy (P = 0.012). It was confirmed in an independent validation cohort of 6… (full text at CIViC) PMID 29301960 · Miao et al., 2018 · Open in CIViC | civic |
| Nivolumab + PembrolizumabSubstitutes | Renal Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7536Among 35 patients with clear cell RCC, loss-of-function mutation of PBRM1 were correlated with response to anti-PD-1 monotherapy (P = 0.012). It was confirmed in an independent validation cohort of 63… (full text at CIViC) PMID 29301960 · Miao et al., 2018 · Open in CIViC | civic |